An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples

Journal of Lipid Research

Volumn 51, Issue 3, 2010, Pages 652-659

  Zhao, Zhenwen ^a   Xu, Yan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell pellet lipid; HPLC ESI MS MS; MeOH method; Tissue lipid

Indexed keywords

LYSOPHOSPHOLIPID; METHANOL; PHOSPHOLIPID;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; BLOOD SAMPLING; CENTRIFUGATION; CONTROLLED STUDY; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPIDOMICS; PRIORITY JOURNAL; REPRODUCIBILITY; SOLVENT EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; ANIMALS; CELL LINE, TUMOR; CHEMICAL FRACTIONATION; HUMANS; LYSOPHOSPHOLIPIDS; METHANOL; PHOSPHOLIPIDS; REPRODUCIBILITY OF RESULTS;

EID: 77950604843     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D001503     Document Type: Article

References (38)

1. Dennis, E. A., H. A. Brown, R. A. Deems, C. K. Glass, A. H. Merrill, R. C. Murphy, C. R. H. Raetz, W. Shaw, S. Subramaniam, D. W. Russell, et al. 2006. Functional lipodomics. CRC Press, Boca Raton, FL. 1-15.
2. Sasagawa, T., M. Okita, J. Murakami, T. Kato, and A. Watanabe. 1999. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids. 34: 17-21.
3. Drobnik, W., G. Liebisch, F. X. Audebert, D. Frohlich, T. Gluck, P. Vogel, G. Rothe, and G. Schmitz. 2003. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J. Lipid Res. 44: 754-761.
4. Fuchs, B., J. Schiller, U. Wagner, H. Hantzschel, and K. Arnold. 2005. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin. Biochem. 38: 925-933.
5. Ehehalt, R., J. Wagenblast, G. Erben, W. D. Lehmann, U. Hinz, U. Merle, and W. Stremmel. 2004. Phosphatidylcholine and lysophos-phatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrom-etry. Scand. J. Gastroenterol. 39: 737-742.
6. Takatera, A., A. Takeuchi, K. Saiki, T. Morisawa, N. Yokoyama, and M. Matsuo. 2006. Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 838: 31-36.
7. Wenk, M. R. 2005. The emerging field of lipidomics. Nat. Rev. Drug Discov. 4: 594-610.
8. Watson, A. D. 2006. Thematic review series: systems biology ap-proaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J. Lipid Res. 47: 2101-2111.
9. Moolenaar, W. H., L. A. van Meeteren, and B. N. Giepmans. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays. 26: 870-881.
10. Xu, Y., Y. J. Xiao, K. Zhu, L. M. Baudhuin, J. Lu, G. Hong, K. S. Kim, K. L. Cristina, L. Song, S. Williams, P. Elson, M. Markman, and J. Belinson. 2003. Unfolding the pathophysiological role of bioac-tive lysophospholipids. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3: 23-32.
11. Chun, J., and H. Rosen. 2006. Lysophospholipid receptors as po-tential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. 12: 161-171.
12. Moolenaar, W. H. 2000. Development of our current understand-ing of bioactive lysophospholipids. Ann. N. Y. Acad. Sci. 905: 1-10.
13. Sengupta, S., Z. Wang, R. Tipps, and Y. Xu. 2004. Biology of LPA in health and disease. Semin. Cell Dev. Biol. 15: 503-512.
14. Mills, G. B., and W. H. Moolenaar. 2003. The emerging role of lyso-phosphatidic acid in cancer. Nat. Rev. Cancer. 3: 582-591.
15. Kim, K. S., S. Sengupta, M. Berk, Y. G. Kwak, P. F. Escobar, J. Belinson, S. C. Mok, and Y. Xu. 2006. Hypoxia enhances lysophos-phatidic acid responsiveness in ovarian cancer cells and lysophos-phatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 66: 7983-7990.
16. Ren, J., Y. J. Xiao, L. S. Singh, X. Zhao, Z. Zhao, L. Feng, T. M. Rose, G. D. Prestwich, and Y. Xu. 2006. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 66: 3006-3014.
17. Spiegel, S., and S. Milstien. 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4: 397-407.
18. Xu, Y., Z. Shen, D. W. Wiper, M. Wu, R. E. Morton, P. Elson, A. W. Kennedy, J. Belinson, M. Markman, and G. Casey. 1998. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 280: 719-723.
19. Sutphen, R., Y. Xu, G. D. Wilbanks, J. Fiorica, E. C. Grendys, J. P. J. LaPolla, H. Arango, M. S. Hoffman, M. Martino, K. Wakeley, et al. 2004. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13: 1185-1191.
20. Yoon, H. R., H. Kim, and S. H. Cho. 2003. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 788: 85-92.
21. Sedlakova, I., J. Vavrova, J. Tosner, and L. Hanousek. 2006. Lysophosphatidic acid in ovarian cancer patients. Ceska Gynekol. 71: 312-317. (Pubitemid 44252138)
22. Zhao, Z., Y. Xiao, P. Elson, H. Tan, S. J. Plummer, M. Berk, P. P. Aung, I. C. Lavery, J. P. Achkar, L. Li, et al. 2007. Plasma lysophos-phatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 25: 2696-2701.
23. Xiao, Y., and Y. Xu. 2006. Functional lipodomics. CRC Press, Boca Raton, FL. 125-146.
24. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
25. Xiao, Y., Y. Chen, A. W. Kennedy, J. Belinson, and Y. Xu. 2000. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. N. Y. Acad. Sci. 905: 242-259.
26. Xiao, Y. J., B. Schwartz, M. Washington, A. Kennedy, K. Webster, J. Belinson, and Y. Xu. 2001. Electrospray ionization mass spec-trometry analysis of lysophospholipids in human ascitic fl uids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fl uids. Anal. Biochem. 290: 302-313.
27. Yatomi, Y., T. Ohmori, G. Rile, F. Kazama, H. Okamoto, T. Sano, K. Satoh, S. Kume, G. Tigyi, Y. Igarashi, et al. 2000. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 96: 3431-3438.
28. Scherer, M., G. Schmitz, and G. Liebisch. 2009. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatog-raphy-tandem mass spectrometry. Clin. Chem. 55: 1218-1222.
29. Murph, M., T. Tanaka, J. Pang, E. Felix, S. Liu, R. Trost, A. K. Godwin, R. Newman, and G. Mills. 2007. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer for diagnosis. Methods in Enzymology. 433: 1-25.
30. Baker, D. L., P. Morrison, B. Miller, C. A. Riely, B. Tolley, A. M. Westermann, J. M. Bonfrer, E. Bais, W. H. Moolenaar, and G. Tigyi. 2002. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 287: 3081-3082.
31. Liebisch, G., W. Drobnik, B. Lieser, and G. Schmitz. 2002. High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry. Clin. Chem. 48: 2217-2224.
32. Zhang, N., R. Chen, N. Young, D. Wishart, P. Winter, J. H. Weiner, and L. Li. 2007. Comparison of SDS-and methanol-assisted protein solubilization and digestion methods for Escherichia colimem-brane proteome analysis by 2-D LC-MS/MS. Proteomics. 7: 484-493
33. Wellcome Trust Case Control Consortium. 2007. Genome-wide as-sociation study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447: 661-678.
34. Mailman, M. D., M. Feolo, Y. Jin, M. Kimura, K. Tryka, R. Bagoutdinov, L. Hao, A. Kiang, J. Paschall, L. Phan, et al. 2007. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39: 1181-1186.
35. Schiess, R., B. Wollscheid, and R. Aebersold. 2009. Targeted pro-teomic strategy for clinical biomarker discovery. Mol. Oncol. 3: 33-44.
36. Sedláková, I., J. Vávrová, J. Tosner, and L. Hanousek. 2008. Lysophosphatidic acid: an ovarian cancer marker. Eur. J. Gynaecol. Oncol. 29: 511-514.
37. Pozlep, B., M. Meleh, B. Kobal, I. Verdenik, J. Osredkar, L. Z. Kralj, and H. Meden-Vrtovec. 2007. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur. J. Gynaecol. Oncol. 28: 394-399.
38. Meleh, M., B. Pozlep, A. Mlakar, H. Meden-Vrtovec, and L. Zupancic-Kralj. 2007. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858: 287-291.